<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105866">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874262</url>
  </required_header>
  <id_info>
    <org_study_id>ME-CV-1301</org_study_id>
    <nct_id>NCT01874262</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction</brief_title>
  <acronym>SUPPORT</acronym>
  <official_title>A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction - SUPPORT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the mobile-phone based patient support has
      an impact on the adherence and persistence of ticagrelor treatment or on lifestyle changes
      that will have a positive impact on the cardiovascular  risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Adherence</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome will be a composite endpoint consisting of adherence failure events and treatment gaps:
Adherence failure events are defined as more than 14% missed doses during an observation cycle of 7 days. The first missed dose of ticagrelor initiates an observation cycle of 1 week. If a second missed dose is registered within this week an adherence failure event is registered. The third missed dose initiates a new observation cycle, and the process restarts.
Treatment gaps are defined as patient reported gaps of more than 4 consecutive doses during the participation in the study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Active group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The software application used on the patients' smart phones in the active group, will contain both the e-diary and the mobile-phone based patient support. Patients will receive feedback by the mobile-phone based support not only on the data they enter into the mobile-phone based patient support but also on their reported daily ticagrelor use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this group the patients will have access to the e-diary only, in which they will report their daily use of ticagrelor. The patients in the control group will not receive any feed-back.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mobile-phone based patient support</intervention_name>
    <description>The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.</description>
    <arm_group_label>Active group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>e-diary</intervention_name>
    <description>All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.</description>
    <arm_group_label>Active group</arm_group_label>
    <arm_group_label>The control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of written patient informed consent.

          2. Patients must have a smart phone at their disposal and use it on a daily basis.

          3. Female or male aged &gt;18 years, diagnosed with a ST elevation Myocardial Infarction
             (STEMI) or non ST elevation Myocardial Infarction (NSTEMI) and treated with
             ticagrelor prior to inclusion into this study and for which the treating physician
             intend to continue prescribing ticagrelor according to the prescription
             recommendation.

          4. Ability to read, understand and write Swedish.

        Exclusion Criteria:

          1. Participation in any clinical trial or device study in the last 30 days excluding
             prospective/retrospective register based studies that do not require any extra visits
             in addition to ordinary health care.

          2. Patients not suitable for participation based on the investigators judgment for
             example:

               -  Patients on treatment with triple antithrombotic treatment.

               -  Patients on treatment with anticoagulantia.

               -  Patients accepted/with a plan for thoracic surgery (CABG) or any other elective
                  surgery that cannot be postponed until after study participation.

               -  Patients with a life expectancy of less than 12 months.

               -  Patients judged to be unable to follow a structured physical activity program.

          3. Patients those are pregnant or lactating.

          4. Patients involved in the planning and/or conduct of the study (applies to AstraZeneca
             staff and/or staff at the study site and application developer).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Varenhorst, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kardiologkliniken, Akademiska Sjukhuset Uppsala</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanna Pozarek</last_name>
    <email>susanna.pozarek@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kardiologi Dagvård, Gröna stråket 2, Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken, Hjärtsektionen, Länssjukhuset Ryhov</name>
      <address>
        <city>Jönköping</city>
        <zip>551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken Köping, Västmanlands sjukhus Köping</name>
      <address>
        <city>Köping</city>
        <zip>73181</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kardiologiska kliniken, Hjärtcentrum, Universitetssjukhuset Linköping</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken Nyköpings Lasarett</name>
      <address>
        <city>Nyköping</city>
        <zip>611 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hjärtmottagningen Capio S:t Görans sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hjärtkliniken, Karolinska Universitetssjukhuset, Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hjärtkliniken, Danderyds Sjukhus AB</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kardiologisektionen Medicinkliniken, Länssjukhuset Sundsvall</name>
      <address>
        <city>Sundsvall</city>
        <zip>851 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hjärtmottagningen, Hjärtcentrum, Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kardiologkliniken, Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christoph Varenhorst Varenhorst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken, Hallands sjukhus Varberg</name>
      <address>
        <city>Varberg</city>
        <zip>43281</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hjärtsektionen, Medicinkliniken, Västmanlands Sjukhus Västerås</name>
      <address>
        <city>Västerås</city>
        <zip>721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hjärtmottagningen CLV, Medicinkliniken, Centrallasarettet Växsjö</name>
      <address>
        <city>Växjö</city>
        <zip>351 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kardiologiska kliniken, Universitetssjukhuset Örebro</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Kellerth</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
